422 related articles for article (PubMed ID: 26890495)
21. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
Bridoux F; Arnulf B; Karlin L; Blin N; Rabot N; Macro M; Audard V; Belhadj K; Pegourie B; Gobert P; Cornec Le Gall E; Joly B; Karras A; Jaccard A; Augeul-Meunier K; Manier S; Royer B; Caillot D; Tiab M; Delbes S; Suarez F; Vigneau C; Caillard S; Arakelyan-Laboure N; Roos-Weil D; Chevret S; Fermand JP;
J Clin Oncol; 2020 Aug; 38(23):2647-2657. PubMed ID: 32574117
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
23. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
26. Hemodialysis: an appropriate therapy in myeloma-induced renal failure.
Sharland A; Snowdon L; Joshua DE; Gibson J; Tiller DJ
Am J Kidney Dis; 1997 Dec; 30(6):786-92. PubMed ID: 9398122
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.
Hutchison CA; Bradwell AR; Cook M; Basnayake K; Basu S; Harding S; Hattersley J; Evans ND; Chappel MJ; Sampson P; Foggensteiner L; Adu D; Cockwell P
Clin J Am Soc Nephrol; 2009 Apr; 4(4):745-54. PubMed ID: 19339414
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
29. Reply. Kastritis E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimes and the impact of novel agents. Haematologica 2007; 92:546-9.
Bergner R; Hoffmann M; Uppenkamp M
Haematologica; 2008 Jan; 93(1):e18-9. PubMed ID: 18166771
[No Abstract] [Full Text] [Related]
30. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
32. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Pönisch W; Holzvogt B; Plötze M; Andrea M; Bourgeois M; Heyn S; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Winkelmann C; Krahl R; Remane Y; Hennig E; Schliwa T; Lindner T; Kaiser T; Vucinic V; Behre G; Niederwieser D
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1947-56. PubMed ID: 24942335
[TBL] [Abstract][Full Text] [Related]
34. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
[TBL] [Abstract][Full Text] [Related]
35. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P
Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588
[TBL] [Abstract][Full Text] [Related]
36. Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters.
Berni Wennekers A; Martín Azara MP; Dourdil Sahun V; Bergasa Liberal B; Ruiz Laiglesia JE; Vernet Perna P; Alvarez Lipe R
Nefrologia; 2016; 36(4):418-26. PubMed ID: 27255910
[TBL] [Abstract][Full Text] [Related]
37. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
40. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]